SAFETY, TOLERABILITY AND PHARMACOKINETICS OF CIPROFLOXACIN DRY POWDER FOR INHALATION IN ADOLESCENT PATIENTS WITH CF

被引：0
|
作者：
Stass, H. [1 ]
Nagelschmitz, J. [1 ]
Posselt, H. [2 ]
机构：
[1] Bayer Schering Pharma AG, Wuppertal, Germany
[2] Goethe Univ Frankfurt, Frankfurt, Germany
来源：
PEDIATRIC PULMONOLOGY | 2009年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
258
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [1] Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin Dry Powder For Inhalation In Patients With Mild To Moderate Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
    Stass, H.
    Nagelschmitz, J.
    Weimann, B.
    Timmer, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [2] Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD
    Stass, Heino
    Nagelschmitz, Johannes
    Watz, Henrik
    Kirsten, Anne Marie
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [3] Efficacy and Tolerability of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in Bronchiectasis (Non-CF Etiology): Results From the Phase III RESPIRE 1 Study
    De Soyza, Anthony
    Aksamit, Timothy
    Bandel, Tiemo-Joerg
    Criollo, Margarita
    Elborn, J. Stuart
    Krahn, Ulrike
    Lau, Maxine
    Operschall, Elisabeth
    Polverino, Eva
    Winthrop, Kevin
    Wilson, Robert
    CHEST, 2016, 150 (04) : 1315A - 1315A
  • [4] Safety, Tolerability and Pharmacokinetics of Novel Liposomal Ciprofloxacin formulations for inhalation in Healthy volunteers and Non-Cystic bronchiectasis Patients
    Bruinenberg, P.
    Serisier, D.
    Cipolla, D.
    Blanchard, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [5] Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A Phase I, Randomized, Dose-Escalation Study
    Stass, Heino
    Weimann, Boris
    Nagelschmitz, Johannes
    Rolinck-Werninghaus, Claudia
    Staab, Doris
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1571 - 1581
  • [6] Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics
    Billiard, Julia
    Baker, Stephen
    Chandrasekaran, Vijayalakshmi
    van den Berg, Frans
    Yang, Shuying
    Dumont, Etienne
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [7] Preparation, evaluation and characterization of ciprofloxacin dry powder for inhalation (DPI)
    Ahmed, R. O.
    Kan, P. L.
    Awad, G. A. S.
    Mortada, N. D.
    El-Shamy, A. H.
    Alpar, H. O.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 : A52 - A52
  • [8] Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study
    Stass, Heino
    Delesen, Heinz
    Nagelschmitz, Johannes
    Staab, Doris
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2015, 28 (02) : 106 - 115
  • [9] Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis
    Stass, Heino
    Nagelschmitz, Johannes
    Kappeler, Dominik
    Sommerer, Knut
    Patzlaff, Astrid
    Weimann, Boris
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2019, 32 (03) : 156 - 163
  • [10] SOLID STATE MODIFICATION OF CIPROFLOXACIN FOR HIGH DOSE DRY POWDER INHALATION
    Hibbard, Thomas
    Al-Obaidi, Hisham
    Shankland, Kenneth
    Nyambura, Bildad
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2021, 34 (03) : A17 - A17
12345